Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimaret al
Open Access
- 9 September 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (10), e204
- https://doi.org/10.1136/annrheumdis-2020-218710
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Tocilizumab treatment for polyarteritis nodosaRheumatology, 2020
- Tocilizumab Treatment in Polyarteritis Nodosa2019
- Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trialAnnals Of The Rheumatic Diseases, 2018
- Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)Annals Of The Rheumatic Diseases, 2018
- Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?RMD Open, 2017
- Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosaAmyloid, 2016
- Tofacitinib for polyarteritis nodosa: a tailored therapyAnnals Of The Rheumatic Diseases, 2016
- Polyarteritis nodosa: A contemporary overviewAutoimmunity Reviews, 2016
- A Case of Polyarteritis Nodosa Associated with Vertebral Artery Vasculitis Treated Successfully with Tocilizumab and CyclophosphamideCase Reports in Pediatrics, 2016
- Serum Levels of Interleukin-6 in Patients with Cutaneous Polyarteritis NodosaActa Dermato-Venereologica, 2012